BioNTech Management
Management criteria checks 2/4
We currently do not have sufficient information about the CEO.
Key information
Ugur Sahin
Chief executive officer
€264.9m
Total compensation
| CEO salary percentage | 0.26% |
| CEO tenure | 18yrs |
| CEO ownership | 17.5% |
| Management average tenure | 3yrs |
| Board average tenure | 5.8yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2025 | n/a | n/a | -€572m |
| Jun 30 2025 | n/a | n/a | -€345m |
| Mar 31 2025 | n/a | n/a | -€766m |
| Dec 31 2024 | €265m | €700k | -€665m |
| Sep 30 2024 | n/a | n/a | -€467m |
| Jun 30 2024 | n/a | n/a | -€504m |
| Mar 31 2024 | n/a | n/a | €113m |
| Dec 31 2023 | €1m | €700k | €930m |
| Sep 30 2023 | n/a | n/a | €3b |
| Jun 30 2023 | n/a | n/a | €4b |
| Mar 31 2023 | n/a | n/a | €6b |
| Dec 31 2022 | €6m | €360k | €9b |
| Sep 30 2022 | n/a | n/a | €10b |
| Jun 30 2022 | n/a | n/a | €12b |
| Mar 31 2022 | n/a | n/a | €13b |
| Dec 31 2021 | €12m | €360k | €10b |
| Sep 30 2021 | n/a | n/a | €7b |
| Jun 30 2021 | n/a | n/a | €4b |
| Mar 31 2021 | n/a | n/a | €1b |
| Dec 31 2020 | €17m | €360k | €15m |
| Sep 30 2020 | n/a | n/a | -€410m |
| Jun 30 2020 | n/a | n/a | -€230m |
| Mar 31 2020 | n/a | n/a | -€192m |
| Dec 31 2019 | €7m | €311k | -€179m |
Compensation vs Market: Ugur's total compensation ($USD310.24M) is above average for companies of similar size in the German market ($USD5.43M).
Compensation vs Earnings: Ugur's compensation has increased whilst the company is unprofitable.
CEO
Ugur Sahin (60 yo)
Dr. Ugur Sahin, MD, is Co-Founder & CEO of BioNTech US Inc. Dr. Sahin has M.D. from Universität zu Köln in 1990. He is the Chief Executive Officer and Co-Founder of BioNTech SE since 2008 and serves as its...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 18yrs | €264.88m | 17.54% € 3.5b | |
| Co-Founder | 8yrs | €2.53m | 0.33% € 65.0m | |
| MD, COO & Member of Management Board | 12yrs | €2.57m | 0.32% € 63.4m | |
| Chief Legal & Business Officer and Member of the Management Board | 2.3yrs | €881.00k | 0.00033% € 65.5k | |
| Chief Commercial Officer & Member of Management Board | no data | €1.73m | no data | |
| CFO & Member of Management Board | less than a year | no data | no data | |
| Senior Vice President of Global Financial Reporting & Accounting | 1.3yrs | no data | no data | |
| Vice President of Strategy & Investor Relations | no data | no data | no data | |
| Vice President Corporate Communications | no data | no data | no data | |
| Senior Vice President of Global Human Resources | 3yrs | no data | no data | |
| Senior Vice President of Operations | no data | no data | no data | |
| Senior Vice President of Immunotherapy & Preclinical Research | no data | no data | no data |
Experienced Management: 22UA's management team is considered experienced (3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Supervisory Board Member | 3.6yrs | €114.00k | 0.00017% € 33.7k | |
| Independent Deputy Chairman Supervisory Board | 8yrs | €157.00k | 0.00062% € 123.1k | |
| Independent Supervisory Board Member | 18yrs | €100.00k | no data | |
| Independent Supervisory Board Chairman | 18yrs | €288.00k | 0.14% € 27.4m | |
| Member of Supervisory Board | 2.7yrs | €100.00k | no data | |
| Supervisory Board Member | 3.6yrs | €130.00k | 0.00010% € 19.9k |
Experienced Board: 22UA's board of directors are considered experienced (5.8 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/01/05 15:19 |
| End of Day Share Price | 2026/01/05 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
BioNTech SE is covered by 34 analysts. 17 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Harry Gillis | Berenberg |
| Zhiqiang Shu | Berenberg |
| Evan Seigerman | BMO Capital Markets Equity Research |